semaglutide approval FDA approves obesity drug that helped people cut weight 15% Novo Nordisk's EU approval for

Neither is simple

Phase 3 data (TRIUMPH-4) showed average weight loss of 28.7% body weight at the 12mg dose over 68 weeks, equivalent to approximately 71.2 pounds from an average starting weight of 248.5 pounds

Not actual weight, but reducing belly fat -Steve I have been administering Egrifta now for 2 1/2 months, with absolutely no reduction of abdominal fat

The drugs were reaching people far beyond the severe-pain patients the label was written for, and the pipeline kept feeding the supply

Bradlow RCJ, Berk M, Kalivas PW, Back SE, Kanaan RA

Both medications help a large proportion of users achieve clinically significant weight loss (5%)